ABC transporter gene expression in benign and malignant ovarian tissue

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 198-201

  Auner, Veronika ^a   Sehouli, Jalid ^b   Oskay Oezcelik, Gülten ^b   Horvat, Reinhard ^c   Speiser, Paul ^a   Zeillinger, Robert ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transporter; Multiple drug resistance; Ovarian carcinoma

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN ABCB3; PROTEIN ABCC1; PROTEIN ABCC2; PROTEIN ABCC3; PROTEIN ABCC5; PROTEIN ABCC7; PROTEIN ABCF2; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TISSUE LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYSTADENOMA; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; ROC CURVE; UP-REGULATION;

EID: 77950189745     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.077     Document Type: Article

References (35)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16 (2005) 481-488
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58 (2008) 71-96
3. Garcia M., Jemal A., Ward E., Center M., Hao Y., Siegel R., et al. Global cancer facts & figures 2007 (2007), American Cancer Society, Atlanta, GA 1-52
4. Palayekar M.J., and Herzog T.J. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 879-890
5. Materna V., Pleger J., Hoffmann U., and Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol. Oncol. 94 (2004) 152-160
6. Chobanian N, Dietrich CS, 3rd. Ovarian cancer. Surg Clin North Am 2008;88: 285-99, vi.
7. Dean M., Hamon Y., and Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid. Res. 42 (2001) 1007-1017
8. Dean M., and Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33 (2001) 475-479
9. Altman D.G., and Bland J.M. Diagnostic tests 3: receiver operating characteristic plots. BMJ 309 (1994) 188
10. Shaffer J.P. Modified sequentially rejective multiple test procedures. J. Am. Stat. Assoc. 81 (1986) 826-831
11. Roninson I.B., Chin J.E., Choi K.G., Gros P., Housman D.E., Fojo A., et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 4538-4542
12. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
13. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15665-15670
14. Penson R.T., Oliva E., Skates S.J., Glyptis T., Fuller Jr. A.F., Goodman A., et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 93 (2004) 98-106
15. Abele R., and Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 19 (2004) 216-224
16. Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 11 (2005) 67-72
17. Leffers N., Gooden M.J., Mokhova A.A., Kast W.M., Boezen H.M., Ten Hoor K.A., et al. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol. Oncol. 113 (2009) 256-263
18. Han L.Y., Fletcher M.S., Urbauer D.L., Mueller P., Landen C.N., Kamat A.A., et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 14 (2008) 3372-3379
19. Cole S.P., and Deeley R.G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20 (1998) 931-940
20. Nies A.T., and Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453 (2007) 643-659
21. Gerk P.M., and Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 302 (2002) 407-415
22. Belinsky M.G., Dawson P.A., Shchaveleva I., Bain L.J., Wang R., Ling V., et al. Analysis of the in vivo functions of Mrp3. Mol. Pharmacol. 68 (2005) 160-168
23. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
24. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., and Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116 (2005) 824-829
25. O'Brien C., Cavet G., Pandita A., Hu X., Haydu L., Mohan S., et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68 (2008) 5380-5389
26. Kuwano M., Toh S., Uchiumi T., Takano H., Kohno K., and Wada M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des. 14 (1999) 123-131
27. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T., et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 86 (2002) 171-176
28. Ohishi Y., Oda Y., Uchiumi T., Kobayashi H., Hirakawa T., Miyamoto S., et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8 (2002) 3767-3775
29. Kigawa J., Minagawa Y., Cheng X., and Terakawa N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin. Cancer Res. 4 (1998) 1737-1741
30. Wijnholds J., Mol C.A., van Deemter L., de Haas M., Scheffer G.L., Baas F., et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7476-7481
31. Park S., Shimizu C., Shimoyama T., Takeda M., Ando M., Kohno T., et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 99 (2006) 9-17
32. Jia P., Wu S., Li F., Xu Q., Wu M., Chen G., et al. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int. J. Gynecol. Cancer 15 (2005) 1042-1048
33. Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A., et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 64 (2004) 1403-1410
34. Nishimura S., Tsuda H., Ito K., Jobo T., Yaegashi N., Inoue T., et al. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum. Pathol. 38 (2007) 134-139
35. L'Esperance S., Popa I., Bachvarova M., Plante M., Patten N., Wu L., et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int. J. Oncol. 29 (2006) 5-24